Synthesis of multi-antigenic platforms as vaccine candidates against cancers
暂无分享,去创建一个
[1] R. Roy,et al. Glycodendrimers as functional antigens and antitumor vaccines , 2012 .
[2] L. Morelli,et al. Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation , 2011 .
[3] E. Schmitt,et al. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. , 2010, Angewandte Chemie.
[4] A. Nesburn,et al. Linear and Branched Glyco-Lipopeptide Vaccines Follow Distinct Cross-Presentation Pathways and Generate Different Magnitudes of Antitumor Immunity , 2010, PloS one.
[5] Zhongwu Guo,et al. Recent development in carbohydrate-based cancer vaccines. , 2009, Current opinion in chemical biology.
[6] S. Danishefsky,et al. A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis. , 2009, Journal of the American Chemical Society.
[7] G. Boons,et al. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. , 2009, Chemical communications.
[8] F. Bonhomme,et al. Induction of a Melanoma‐Specific Antibody Response by a Monovalent, but not a Divalent, Synthetic GM2 Neoglycopeptide , 2009, ChemMedChem.
[9] L. BenMohamed,et al. Towards a Self‐Adjuvanting Multivalent B and T cell Epitope Containing Synthetic Glycolipopeptide Cancer Vaccine , 2008, ChemMedChem.
[10] P. Labbé,et al. Randomized combinatorial library of heteroglycoclusters (hGC). , 2008, Journal of combinatorial chemistry.
[11] O. Renaudet,et al. Ethoxyethylidene protecting group prevents N-overacylation in aminooxy peptide synthesis , 2007 .
[12] M. Wolfert,et al. Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.
[13] A. Delmas,et al. Synthesis and Biological Evaluation of a Multiantigenic Tn/TF‐Containing Glycopeptide Mimic of the Tumor‐Related MUC1 Glycoprotein , 2006, ChemMedChem.
[14] H. Kunz,et al. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin. , 2005, Angewandte Chemie.
[15] E. Schmitt,et al. A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response. , 2005, Angewandte Chemie.
[16] S. Chierici,et al. Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. , 2005, Bioconjugate chemistry.
[17] C. Bertozzi,et al. Glycans in cancer and inflammation — potential for therapeutics and diagnostics , 2005, Nature Reviews Drug Discovery.
[18] S. Itzkowitz,et al. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients , 1995, Cancer Immunology, Immunotherapy.
[19] S. Danishefsky,et al. On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[20] W. Bornmann,et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. , 2002, Vaccine.
[21] O. Renaudet,et al. Expedient synthesis of aminooxylated-carbohydrates for chemoselective access of glycoconjugates , 2001 .
[22] C. Leclerc,et al. Anti-Tumor Immunity Provided by a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri-Tn Glycotope1 , 2001, The Journal of Immunology.
[23] S. Hakomori,et al. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. , 2001, Advances in experimental medicine and biology.
[24] Allen,et al. From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix. , 2000, Angewandte Chemie.
[25] H. Scher,et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] C. Leclerc,et al. A fully synthetic immunogen carrying a carcinoma-associated carbohydrate for active specific immunotherapy. , 1999, Cancer research.
[27] S. Kuduk,et al. Synthetic and Immunological Studies on Clustered Modes of Mucin-Related Tn and TF O-Linked Antigens: The Preparation of a Glycopeptide-Based Vaccine for Clinical Trials against Prostate Cancer† , 1998 .
[28] C. Cordon-Cardo,et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides , 1997, International journal of cancer.
[29] M. Fukuda. Possible roles of tumor-associated carbohydrate antigens. , 1996, Cancer research.
[30] K. Geoghegan,et al. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. , 1992, Bioconjugate chemistry.
[31] T. Feizi,et al. Carbohydrate structures of glycoproteins and glycolipids as differentiation antigens, tumour-associated antigens and components of receptor systems , 1985 .
[32] S. Hakomori,et al. Tumor-associated carbohydrate antigens. , 1984, Annual review of immunology.